The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans

Amir Tirosh, Ediz S. Calay, Gurol Tuncman, Kathryn C. Claiborn, Karen E. Inouye, Kosei Eguchi, Michael Alcala, Moran Rathaus, Kenneth S. Hollander, Idit Ron, Rinat Livne, Yoriko Heianza, Lu Qi, Iris Shai, Rajesh Garg, Gökhan S. Hotamisligil

Research output: Contribution to journalArticlepeer-review

151 Scopus citations


The short-chain fatty acid propionate is a potent inhibitor of molds that is widely used as a food preservative and endogenously produced by gut microbiota. Although generally recognized as safe by the U.S. Food and Drug Administration, the metabolic effects of propionate consumption in humans are unclear. Here, we report that propionate stimulates glycogenolysis and hyperglycemia in mice by increasing plasma concentrations of glucagon and fatty acid–binding protein 4 (FABP4). Fabp4-deficient mice and mice lacking liver glucagon receptor were protected from the effects of propionate. Although propionate did not directly promote glucagon or FABP4 secretion in ex vivo rodent pancreatic islets and adipose tissue models, respectively, it activated the sympathetic nervous system in mice, leading to secretion of these hormones in vivo. This effect could be blocked by the pharmacological inhibition of norepinephrine, which prevented propionate-induced hyperglycemia in mice. In a randomized, double-blind, placebo-controlled study in humans, consumption of a propionate-containing mixed meal resulted in a postprandial increase in plasma glucagon, FABP4, and norepinephrine, leading to insulin resistance and compensatory hyperinsulinemia. Chronic exposure of mice to a propionate dose equivalent to that used for food preservation resulted in gradual weight gain. In humans, plasma propionate decreased with weight loss in the Dietary Intervention Randomized Controlled Trial (DIRECT) and served as an independent predictor of improved insulin sensitivity. Thus, propionate may activate a catecholamine-mediated increase in insulin counter-regulatory signals, leading to insulin resistance and hyperinsulinemia, which, over time, may promote adiposity and metabolic abnormalities. Further evaluation of the metabolic consequences of propionate consumption is warranted.

Original languageEnglish
Article numbereaav0120
JournalScience Translational Medicine
Issue number489
StatePublished - 24 Apr 2019

ASJC Scopus subject areas

  • Medicine (all)


Dive into the research topics of 'The short-chain fatty acid propionate increases glucagon and FABP4 production, impairing insulin action in mice and humans'. Together they form a unique fingerprint.

Cite this